外傷(Trauma)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Trauma Overview 6
Therapeutics Development 7
Pipeline Products for Trauma – Overview 7
Pipeline Products for Trauma – Comparative Analysis 8
Trauma – Therapeutics under Development by Companies 9
Trauma – Therapeutics under Investigation by Universities/Institutes 10
Trauma – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Trauma – Products under Development by Companies 13
Trauma – Products under Investigation by Universities/Institutes 14
Trauma – Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Bionature E.A. Ltd. 16
Edge Therapeutics, Inc. 17
SanBio, Inc. 18
Trauma – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
EG-1962 – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MEDI-8111 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PT-00114 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PT-00311 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SB-308 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Agonize Neurotrophin Receptor for CNS and Ophthalmological Disorders – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TPX-100 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Trauma – Recent Pipeline Updates 39
Trauma – Dormant Projects 41
Trauma – Discontinued Products 42
Trauma – Product Development Milestones 43
Featured News & Press Releases 43
Jun 10, 2013: Edge Therapeutics Announces FDA Accepts IND Application For EG-1962 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45